Bioversys, Hackensack Meridian Health partner on NTM treatment

Bioversys, Hackensack Meridian Health partner on NTM treatment

Bioversys has entered into an exclusive collaboration and license agreement with Hackensack Meridian Health (HMH) and its Center for Discovery and Innovation to advance a novel class of antibiotics targeting hard-to-treat nontuberculous mycobacteria (NTM) infections, an important concern for people with cystic fibrosis (CF). Under the agreement, the parties will jointly develop novel ansamycin antibiotics that originate from HMH, a not-for-profi…